Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a near universal first quarter stumble, big and medium cap pharma companies finished the half in style, with stocks up $190bn since the end of 2019. The picture is even better for…
Report library
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Mega-deals mask a significant decline in M&A activity for pharma and medtech The Evaluate Vantage Half-Year Review 2019 summaries the most significant trends across…
EvaluatePharma World Preview 2019, Outlook to 2024
Worldwide prescription drugs sales predicted to reach $1.18trn in 2024, with a compound annual growth of 6.9%, significantly higher than the 1.7% CAGR between…
EvaluatePharma Orphan Drug Report 2019
$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a…
Vantage Pharma, Biotech and Medtech 2018 in Review
Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong The Vantage 2018 in Review paints a mixed picture for…
Vantage 2019 Preview
2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…
